C-Maf expression in angioimmunoblastic T-cell lymphoma

American Journal of Surgical Pathology

Volumn 31, Issue 11, 2007, Pages 1695-1702

  Murakami, Yoshiko Idate ^a,h   Yatabe, Yasushi ^b   Sakaguchi, Teruhiro ^a   Sasaki, Eiichi ^a,b   Yamashita, Yoriko ^a   Morito, Naoki ^c   Yoh, Keigyou ^c   Fujioka, Yuuki ^c   Matsuno, Fumihiko ^e   Hata, Hiroyuki ^e   Mitsuya, Hiroaki ^e   Imagawa, Shigehiko ^d   Suzuki, Atsushi ^f   Esumi, Hiroyasu ^f   Sakai, Masaharu ^g   Takahashi, Satoru ^c   Mori, Naoyoshi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^g HOKKAIDO UNIVERSITY   (Japan)

^h NONE   (Japan)

Author keywords

Angioimmunoblastic T cell lymphoma (AILT); c Maf expression; Clear cell

Indexed keywords

CD20 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CYCLIN D1; CYCLIN D2; LEUKOSIALIN; TRANSCRIPTION FACTOR C MAF;

ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; CELL CYCLE PROGRESSION; CELL STIMULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLASTIC LYMPHOMA; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOMA; MULTIPLE MYELOMA; MYCOSIS FUNGOIDES; NATURAL KILLER T CELL; PERIPHERAL T CELL LYMPHOMA; PROTEIN EXPRESSION; REACTION ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STUDENT T TEST; T CELL LEUKEMIA; T CELL LYMPHOMA;

EID: 37349053031     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318054dbcf     Document Type: Article

References (44)

1. Anagnostopoulos I, Hummel M, Finn T, et al. Heterogenous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood. 1992;80:1804-1812.
2. Attygalle A, Al-Jehani R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627-633.
3. Attygalle AD, Diss TC, Munson P, et al. CD10 expression in extranodal dissemination of angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2004;28:54-61.
4. Bornkamm GW, Stein H, Lennert K, et al. Attempts to demonstrate virus-specific sequences in human tumors. IV. EB viral DNA in European Burkitt lymphoma and immunoblastic lymphadenopathy with excessive plasmacytosis. Int J Cancer. 1976;17:177-181.
5. Chang JKC, Chen Y, Shibata D, et al. Description of an in situ Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diag Mol Pathol. 1990;1:246-255.
6. Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-Maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998;91:4457-4463.
7. Dorfman DM, Brown JA, Shahsafaei A, et al. Programmed death-1 (PD-1) is a marker of germinal center-associated T-cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802-810.
8. Dupis J, Boye K, Martin N, et al. Expression of CXCL13 by Neoplastic cells in angioimmunoblastic T-cell lymphoma (AILT). Am J Surg Pathol. 2006;30:490-494.
9. Feller AC, Griesser H, Schilling CV, et al. Clonal gene rearrangement patterns correlate with immunophenotypic and clinical parameters in patients with angioimmunoblastic lymphadenopathy. Am J Pathol. 1988;133:549-556.
10. Frizerra G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinemia. Lancet. 1974;1:1070-1073.
11. Frizerra G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course. Am J Med. 1975;59:803-818.
12. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
13. Ho I-C, Hodge MR, Rooney JW, et al. The proto-oncogene c-Maf is responsible for tissue-specific expression of interleukin-4. Cell. 1996;85:973-983.
14. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
15. Hurt EM, Wiestner A, Rosenwald A, et al. Overexpression of c-Maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5:191-199.
16. Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
17. Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumors. Pathology & Genetics, Tumors of Haematopoietic and Lymphoid Tissues. In: Page Jaffe ES, Ralfkiaer E, eds. Angioimmunoblastic T-cell lymphoma. Lyon: IARC press; 2001:225-226.
18. Kataoka K, Nishizawa M, Kawai S. Structure-function analysis of the maf oncogene product, a member of the zip-protein family. J Virol. 1993;67:2133-2141.
19. Kienast J, Berdel WE. C-Maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions. Cancer Cell. 2004;5:109-110.
20. Knecht H, Sahli R, Shaw P, et al. Detection of Epstein-Barr virus DNA by polymerase chain reaction in lymph node biopsies from patients with angioimmunoblastic lymphadenopathy. Br J Haematol. 1990;75:610-614.
21. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nature Rev Cancer. 2002;2:175-187.
22. Kurschner C, Morgan JI. The maf proto-oncogene stimulates transcription from multiple sites in a promotor that directs Purkinje neuron-specific gene expression. Mol Cell Biol. 1995;15:246-254.
23. Lee S-S, Ruediger T, Odenwald T, et al. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer. 2003;103:12-20.
24. Lipford EH, Smith HR, Pittaluga S, et al. Clonality of angioimmunoblastic lymphadenopathy and implications for its evolution to malignant lymphoma. J Clin Invest. 1987;79:637-642.
25. Lukes RJ, Tindle BH. Immunoblastic lympadenopathy. A hyperimmune entity resembling Hodgkin's disease. N Engl J Med. 1975;292:1-8.
26. Lukes RJ, Tindle BH. Immunoblastic lymphadenopathy: a prelymphomatous state of immunoblastic sarcoma. Recent Results Cancer Res. 1978;64:241-246.
27. Mclean IW, Nakane PK. Periodate-lysin-paraformaldehyde fixative: a new fixative for immunoelectron microscopy. J Histochem Cytochem. 1974;22:1077-1083.
28. Morito N, Yoh K, Fujioka Y, et al. Overexpression of c-Maf contributes to T-cell lymphoma in both the mouse and human. Cancer Res. 2006;66:812-819.
29. Namikawa R, Suchi T, Ueda R, et al. Phenotyping of proliferating lymphocytes in angioimmunoblastic lymphadenopathy and related lesions by the double immunoenzymatic staining technique. Am J Pathol. 1987;127:279-287.
30. Nishizawa M, Kataoka K, Goto N, et al. V-Maf, a viral oncogene that encode a "leucine zipper" motif. Proc Natl Acad Sci USA. 1989;86:7711-7715.
31. O'Connor NT, Crick JA, Wainscoat JS, et al. Evidence for monoclonal T lymphocyte proliferation in angioimmunoblastic lymphadenopathy. J Clin Pathol. 1986;39:1229-1232.
32. Ohnishi K, Ichikawa A, Kagami Y, et al. Interleukin 4 and g-interferon may play a role in the histopathogenesis of peripheral T-cell lymphoma. Cancer Res. 1990;50:8028-8033.
33. Radakiewicz T, Lenner K. Lymphogranulamatosis X: Klinisches bild, therapie und prognose. Dtsch Med Wschr. 1975;100:1157-1163.
34. Seidi S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol. 2003;4:557-564.
35. Shimoyama M, Minato K, Saito H, et al. Immunoblastic lymphadenopathy (IBL)-like T-cell lymphoma. Jpn J Clin Oncol. 1979;9:347-356.
36. Suchi T, Lennert K, Tu LY, et al. Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification. J Clin Pathol. 1987;40:995-1015.
37. Suzuki H, Namikawa R, Ueda R, et al. Clonal T cell population in angioimmunoblastic lymphadenopathy and related lesions. Jpn J Cancer Res. 1987;78:712-720.
38. Tobinai K, Minato K, Ohtsu T, et al. Clinicopathologic, immunophenotypic and immunogenotypic analysis of immunoblastic lymphadenopathy-like T cell lymphoma. Blood. 1988;72:1000-1006.
39. von Forster G, Moeschlin S. Extramedullaeres, leukaemisches Plasmocytom mit dysproteinaemie und erworbener haemolytischer Anaemie. Schweiz Med Wochenschr. 1954;84:1106-1110.
40. Watanabe S, Sato Y, Shimoyama M, et al. Immunoblastic lymphadenopathy, angioimmunoblastic lymphadenopathy and IBL-like T cell lymphoma. A spectrum of T cell neoplasia. Cancer. 1986;58:2224-2232.
41. Weiss LM, Strickler JG, Dorfman RF, et al. Clonal T cell population in angioimmunoblastic lymphadenopathy and angioimmunoblastic-like lymphoma. Am J Pathol. 1986;122:392-397.
42. Weiss LM, Jaffe ES, Liu X-F, et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy-like lymphoma. Blood. 1992;79:1789-1795.
43. Willenbrock K, Roers A, Seidl C, et al. Analysis of T-cell subpopulation in T-cell non-Hodgkin's lymphoma of angioimmunoblastic lymphadenopathy with dysproteinemia type by single target gene amplification of T cell receptor-β gene rearrangement. Am J Pathol. 2001;158:1851-1857.
44. Zao W-L, Mourah S, Mounier N, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest. 2004;84:1512-1519.